PRESS RELEASE: 25 January 2022, 07:00 CET
Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes
- Lung cancer accounts for the largest number of cancer deaths worldwide
- 102 Idylla™ EGFR Mutation Test (CE-IVD) results of lung adenocarcinoma patients1 were compared with NGS
- 6 percent of the patients died before the NGS report was available; of the 17 patients whose condition deteriorated rapidly, 3 (18 percent) were identified as having an actionable variant in EGFR that could have been treated with tyrosine kinase inhibitors
- Average turnaround time to report EGFR mutations with the Idylla™ EGFR Mutation Test was 3.8 days, versus 17 days on average for reporting of NGS results through an external laboratory
Mechelen, Belgium, 25 January 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the publication of a large new study2 comparing the difference in turnaround time between in-house automated rapid PCR3-based EGFR analysis and Next-Generation Sequencing (NGS) by an external laboratory, with a focus on patient health outcome. The study concluded that a dual PCR and NGS testing strategy for stage IV non-squamous, non-small cell lung cancer (NSCLC) patients has the potential to improve care and survival outcomes by providing access to the right test at the right time.
Lung cancer accounts for the largest number of cancer deaths worldwide, as such there is an opportunity to significantly impact patient outcomes through earlier intervention4. EGFR or ‘Epidermal Growth Factor Receptor’ mutations are the second most common cancer driver mutation in NSCLC. EGFR testing is important for the detection of EGFR mutations which help to determine whether someone with NSCLC may benefit from targeted therapy-based regimens in case of presence of EGFR mutations, or potentially from immunotherapy-based regimens in case of absence of EGFR mutations5. EGFR mutations are commonly assessed by using NGS. This is a complex and time-consuming technology, which may delay informed patient management decisions for patients with NSCLC.
In the study, 102 test results for lung adenocarcinoma patients were compared using both NGS and Idylla™ EGFR Mutation Test (CE-IVD)6. Unfortunately, 6% of the patients died before the NGS report was available. Of the 17 patients whose condition deteriorated rapidly, 3 (18%) were identified as having an actionable variant in EGFR that could have been treated with tyrosine kinase inhibitors. Of 102 tests performed, agreement between the two test modalities was achieved in 96.4% of test events where there was sufficient tissue for testing. Average turnaround time to report EGFR mutations with the Idylla™ EGFR Mutation Test was 3.8 days, versus an average turnaround time of 17 days for reporting of NGS results by an external laboratory.
Furthermore, the study highlights additional benefits of using Idylla™, including minimum staffing time requirements, elimination of the need for batching cases as well as the ability to report biomarker results on the day of the request. Finally, there were 11 occasions where NGS failed to extract sufficient DNA from a test sample and Idylla™ was able to produce a valid report in nine (9/11, 82%) of those instances. Two of the nine tests that failed NGS included patients where an L858R mutation was detected by Idylla™ that went undetected by NGS.
Herman Verrelst, Chief Executive Officer of Biocartis, commented: “The routine reflex of many lung cancer multidisciplinary teams or pathologists is to request NGS testing, which takes place at an external, specialized lab. As such, results take a lot longer than rapid in-house EGFR testing using Idylla™. In the study, 18 percent of stage IV NSCLC patients were at risk of rapid clinical deterioration. This study clearly demonstrates the positive impact the Idylla™ EGFR Mutation Test can potentially have in improving cancer survival rates.”
More information can be found in the study here.
—– END —-
Head of Corporate Communications & Investor Relations Biocartis
tel +32 15 631 729
mobile +32 471 53 60 64
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis’ proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology, which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer, as well as for COVID-19, flu, RSV and sepsis. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_.
Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product.
This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations and projections concerning future events such as the Company’s results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
1 There were 102 Idylla™ EGFR Mutation Tests performed for 96 patients; six patients had repeat testing performed on different specimens or an alternative block where DNA yield was insufficient. The CE-IVD validated Idylla™ EGFR Mutation Test used FFPE (Formalin Fixed, Paraffin Embedded) tissue sections from human NSCLC tissue. In this study, all NSCLC samples were used including cytological FFPE samples
2 A. Finall et al., J Clin Pathol . 2022 Jan 18;jclinpath-2021-207987. doi: 10.1136/jclinpath-2021-207987. Online ahead of print
3 Polymerase Chain Reaction or PCR is a fast and inexpensive technique used to amplify or copy small segments of DNA and used to detect genetic material such as biomarkers that drive cancer
4 Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019
5 Hofman, P. EGFR Status Assessment for Better Care of Early-Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists? Cells 2021, 10, 2157. Link here, first published on 21 Aug 2021
6 Concordance between the Idylla™ EGFR Mutation Test and NGS testing was 96%
The content is by GlobeNewswire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.